Key Trend Reshaping the Proliferative Diabetic Retinopathy (PDR) Market in 2025: Cellevolve Bio's Breakthrough In PML Treatment

What industry-specific factors are fueling the growth of the proliferative diabetic retinopathy (pdr) market?
The growth of the proliferative diabetic retinopathy (PDR) market is projected to be propelled by the increasing incidence of diabetes. Marked by high glucose levels in the blood, diabetes is a long-term health problem that is the main contributor to proliferative diabetic retinopathy disease. This disease can be managed through various techniques designed to prevent further damage to the retina and maintain vision. For example, the National Health Service (NHS) of the UK reported in June 2024 that the number of individuals under 40 with this condition increased from 173,166 in 2022 to 216,440 in 2023. This considerable increase points to a worrying pattern in this age demographic indicating a swift increase in the prevalence of diabetes among younger individuals. Therefore, the proliferative diabetic retinopathy (PDR) market is being driven by the growing prevalence of diabetes. The escalating rate of obesity is also expected to contribute to the growth of the proliferative diabetic retinopathy (PDR) market. Obesity, a complicated and chronic health condition, leads to excessive body fat and often poor health, is linked to insulin resistance, continuous low-grade inflammation, and heightened oxidative stress which can harm the retinal microvasculature and spark the onset of diabetic retinopathy. For example, Trust for America's Health, a non-profit based in the US, disclosed in their 2022 report that obesity rates in the US are on the rise, with obesity affecting four out of every ten American adults. This is a rise from the previous year, with 19 states now reporting adult obesity rates over 35%, a jump from 16 states the previous year. Thus, elevated obesity levels are a key factor driving the growth of the proliferative diabetic retinopathy (PDR) market.

Get Your Proliferative Diabetic Retinopathy (PDR) Market Report Here:
https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

What Is the projected market size and growth rate for the proliferative diabetic retinopathy (pdr) market?
In recent times, the market for proliferative diabetic retinopathy (PDR) has expanded significantly. The market size is projected to escalate from $2.42 billion in 2024 to $2.7 billion in 2025, at a compound annual growth rate (CAGR) of 11.6%. This rapid growth observed in the previous period can be linked to a surge in diabetes incidence, lifestyle alterations, consumption of unhealthy foods, government interventions, and an increased count of vision loss related to diabetes.

The market for proliferative diabetic retinopathy (PDR) is projected to expand rapidly in the upcoming years, reaching a valuation of $4.02 billion by 2029, at a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this growth over the forecast period include an increase in the aged population, heightened awareness and education about diabetes across society, increased funds for research and development, and a growing demand for combination therapies. The forecast period will also see key trends such as enhancement in diagnostic technologies, innovative treatment options, the use of artificial intelligence (AI) for early diagnosis, progress in gene therapy, and advanced retinal imaging.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

What new trends are reshaping the proliferative diabetic retinopathy (pdr) market and its opportunities?
Leading firms in the proliferative diabetic retinopathy market are focusing constantly on introducing innovative therapies aimed at augmenting the effectiveness of treatments, lessening treatment burdens, and bettering patient outcomes. For instance, Biogen, a US biotechnology firm, along with Samsung Bioepis, a South Korean biotech firm, launched Byooviz (ranibizumab-nuna) in June 2022, marking the debut of the first biosimilar in the field of ophthalmology in the US. These products cater to patients suffering from diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.

What major market segments define the scope and growth of the proliferative diabetic retinopathy (pdr) market?
The proliferative diabetic retinopathy (PDR) market covered in this report is segmented -

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy
2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations
3) By Application: Hospitals, Clinics, Other Applications

Subsegments:
1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab
2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

Which regions are key players in the growth of the proliferative diabetic retinopathy (pdr) market?
North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which key market leaders are driving the proliferative diabetic retinopathy (pdr) industry growth?
Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp

What Is Covered In The Proliferative Diabetic Retinopathy (PDR) Global Market Report?

•Market Size Forecast: Examine the proliferative diabetic retinopathy (pdr) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the proliferative diabetic retinopathy (pdr) market for a structured understanding.
•Key Players Overview: Analyze major players in the proliferative diabetic retinopathy (pdr) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the proliferative diabetic retinopathy (pdr) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the proliferative diabetic retinopathy (pdr) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the proliferative diabetic retinopathy (pdr) market.
•Industry Challenges: Identify potential risks and obstacles affecting the proliferative diabetic retinopathy (pdr) market.
•Competitive Landscape: Review strategic developments in the proliferative diabetic retinopathy (pdr) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.